Napatree Capital LLC Purchases Shares of 1,244 Amgen Inc. (NASDAQ:AMGN)

Napatree Capital LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,244 shares of the medical research company’s stock, valued at approximately $358,000.

A number of other large investors have also added to or reduced their stakes in AMGN. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen during the fourth quarter valued at about $29,000. United Community Bank bought a new position in shares of Amgen during the fourth quarter valued at about $29,000. Planned Solutions Inc. bought a new position in shares of Amgen during the fourth quarter valued at about $30,000. Delos Wealth Advisors LLC grew its stake in shares of Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the last quarter. Finally, Providence Capital Advisors LLC bought a new position in shares of Amgen during the third quarter valued at about $30,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.69% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $305.55 on Tuesday. The firm has a 50 day moving average price of $293.45 and a 200-day moving average price of $289.82. Amgen Inc. has a 52-week low of $218.44 and a 52-week high of $329.72. The firm has a market capitalization of $163.91 billion, a price-to-earnings ratio of 43.33, a PEG ratio of 2.70 and a beta of 0.60. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same period last year, the business earned $3.98 earnings per share. The business’s revenue was up 22.0% on a year-over-year basis. Equities research analysts forecast that Amgen Inc. will post 19.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent research reports. TD Cowen reduced their price objective on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday, April 17th. Raymond James assumed coverage on Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating on the stock. Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Mizuho raised their target price on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a research note on Thursday, May 9th. Finally, Morgan Stanley raised their target price on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research note on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $305.85.

Check Out Our Latest Analysis on AMGN

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.